# Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

> **NCT02154490** · — · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 1864 (actual)

## Conditions studied

- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Erlotinib Hydrochloride
- **DRUG:** FGFR Inhibitor AZD4547
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Palbociclib
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Rilotumumab
- **DRUG:** Talazoparib
- **DRUG:** Taselisib
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT02154490
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-08
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-15
- **Target enrollment:** 1864 (ACTUAL)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154490, "Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02154490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*